BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 15306747)

  • 1. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
    Lee MS; Wali AU; Menon V; Berkowitz SD; Thompson TD; Califf RM; Topol EJ; Granger CB; Hochman JS
    J Thromb Thrombolysis; 2002 Oct; 14(2):91-101. PubMed ID: 12714828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.
    Bates SM; Weitz JI; Johnston M; Hirsh J; Ginsberg JS
    Arch Intern Med; 2001 Feb; 161(3):385-91. PubMed ID: 11176764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
    Newby LK; Harrington RA; Bhapkar MV; Van de Werf F; Hochman JS; Granger CB; Simes RJ; Davis CG; Topol EJ; Califf RM; Moliterno DJ;
    J Thromb Thrombolysis; 2002 Aug; 14(1):33-42. PubMed ID: 12652148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].
    Mariné L; Sánchez G; Vargas JF; Zúñiga P; Aizman A; Mertens R; Bergoeing M; Muñoz B
    Rev Med Chil; 2014 Nov; 142(11):1392-7. PubMed ID: 25694284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin.
    Mitsuguro M; Okamoto A; Shironouchi Y; Sano M; Miyata S; Neki R; Araki T; Hamamoto T; Yoshimatsu J; Miyata T
    Int J Hematol; 2015 Feb; 101(2):119-25. PubMed ID: 25416968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK; Thomson AR; Moriarty HT
    Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.
    Toulon P; Smahi M; De Pooter N
    J Thromb Haemost; 2021 Aug; 19(8):2002-2006. PubMed ID: 33555096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.